

Office of The Commissioner, ood & Drugs Administration M.S. andra - Kurla Complex, Bandra (E), Mumbai - 400 051

0 5 DEC 2019

ATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization (General instructions and explanatory notes attached)

Certificate No.: WHO-GMP/CERT/KD/90630/2019/11/30326

On the basis of the inspection carried out on 23/10/2017, 24/10/2017 and 30/11/2017 we certify that the site indicated on this Certificate complies with Good Manufacturing Practices for the dosage forms, categories and activities listed in Table 1.

Name of the Firm

KOPRAN RESEARCH LABORATORIES

Address

Licence No.

K-4/4, ADDITIONAL MIDC, POST BIRWADI,

TAL. MAHAD, DIST. RAIGAD, RAIGAD 402302 MAHARASHTRA STATE, INDIA

KD265 In Form 25.

KD230 In Form 28



NOTARIAL

NOTARIAL

· ya	Dosage Form(s)	Categor(ies)	Activity(ies)	144
Z	Active Pharmaceutical Ingredients (Bulk Drugs)	Cephalusporins	Synthesis Purification Packing Labelling Quality Control Quality Assurance	PROPERTY AND AND THE PROPERTY AND THE PR
1.1	Active Pharmaceutical Ingredients (Bulk Drugs)	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Synthesis Punfication Packing, Labelling, Quality Control, Quality Assurance	
	Active Pharmaceutical Ingredients (Bulk Drugs)	Penems	Synthesis, Purification, Packing, Labelling, Quality Control, Quality Assurance	No 077
2	Granules	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Synthesis, Purification, Packing, Labelling, Quality Control, Quality Assurance	IMC
5/	Peliets	General (Other than Cephalosporins, Penicillin Cytotoxic, Hormones)	Synthesis, Purification, Packing, Labelling, Quality Control, Quality Assurand	SEE OF COMMEN
he re nanut	esponsibility for the quality actured through this proce	of the individual batches of the with the manufacture	Packing, Labelling, Quality Control, Quality Assurance Synthesis, Purification, Packing, Labelling, Quality Control, Quality Assurance of the pharmaceutical product of this certificate has be of this Certificate remains 0stegories certified herewith are	0 4 SFP
he C xtend un 2	Centificate was valid upto ded for the period of six r 020 - It becomes invalid	05 Dec 2019. The validity months and now the validity if the activities and / or ca	y of this certificate has be of this Certificate remains 0s tegories certified herewith are	* MUMBAI, IN

Fun 2020 It becomes invalid if the activities and / or categories certified herewith are thanged or if the site is no longer considered to be in comphance with GMP.

of the Authorised person : V. K. BIYAN

Signature

NO 07791

MUMBAI, INDI

Food & Drug Ad

Bandra (E) Mun

Manarasotra IND

Stamp and Date Joint Commissioner (HQ) & Controlling

Authority Food & Drug Administration, M.S.

Bandra (E), Mumbai.

Maharashtra State, India

ROHIT YAD Manager

AUTHORISED SIGNATORY IMG CHAMBER OF COMMERCE AND INDUSTRY MUMBALINDIA

4 SEP 2020

Explanatory notes

- 1. This certificate which is in the format recommended by WHO, certifies the status in point 1 of the certificate.
- 2. The certification number should be traceable within the regulatory au certificate.
- Where the regulatory authority issues a licence for the site, this number of record "not applicable" in cases where there is no legal framework for the issuing
- Table I List the dosage forms, starting materials, categories and activities. Examples and given below

Example -1

Pharmaceutical Product (s)t	Category (ies)	Activity (ies)	
Dosage form (s)			
Tablets	Cytotoxic	Packaging	
Tablets	Hormone	Production, Packaging. Quality control.	
Injectables	Penicillin	Repackaging & Labelling.	
injections	Cefalosporin	Aseptic preparation. Packaging. Labelling.	

Example - 2.

Pharmaceutical Product (s):	Category (ies)	Activity (ies)
Starting material (s)2 Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available, International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certification





7-5/2020/Misc/070 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi- 110002. Dated:- 1/5/200

To.

All States/UT Drugs Controllers

Subject: Extension of validity of WHO GMP/Certificate of Pharmaceutical Product (COPP) - Regarding

Sir/Madam

Certificate of Pharmaceutical Product (CoPP) is issued under the WHO GMP international commerce, i.e., for registration of countries in foreign countries. Earlier the validity of CoPP was extended from 2 years to 3 is vide Office Memorandum No. 7-5/2018/Misc/048 dated 08.05.2018.

This office has received representations from stakeholders requesting to extend dity of WHO GMP Certificate/CoPP whose validities are expiring between now and just 2020 in view of COVID-19 outbreak.

The matter has been examined in light of current situation of COVID 19 outbreak and dento maintain the continuity of essential activities by the pharmaceutical industry, it has produced that validity of WHO GMP/CoPP expiring from March to August 2020 may be indeed by 6 months; from the date of expiry of the certificate as per WHO GMP fication guidelines.

TOTARIAL

IMC OF COMMERCE AND INDUSTRY

AUTHORISED SIGNATORY

MC CHAMBER OF COMMERCE AND INCKSTRY Faithfully,

MUMBAHINDIA

ROHIT YADAV
Dr. V. G. Somani
Manages Controller General (India)

Copy to:

1- PS to JS (R), NOHME GOI, Nirman Bhawan, New Delhi

2- All Zonal, Sub-Zonal offices of CDSCO

4 SEP 2020

Notary Greater Mumbai